相关实验视频

Updated: Jul 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

希望和挑战:EGFR突变NSCLC患者的免疫疗法

¹Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.

|November 25, 2023

概括

EGFR氨酸激酶抑制剂 (TKIs) 提供初始非小细胞肺癌 (NSCLC) 治疗,但出现耐药性. 免疫疗法在EGFR突变NSCLC中表现出有限的疗效,这是由于非炎症瘤微环境.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

EGFR氨酸激酶抑制剂 (TKI) 是EGFR突变非小细胞肺癌 (NSCLC) 的第一线治疗方法.
瘤对EGFRTKI的耐药性很常见,随后的治疗选择有限.
免疫检查点抑制剂 (ICI) 显示出潜力,但在大多数EGFR突变NSCLC中有效性较低.

研究的目的:

审查ICI治疗在EGFR突变NSCLC中的潜力.
讨论ICI治疗在这个患者群体中的挑战和限制.

主要方法:

临床前研究的审查.
对临床试验数据的分析.
在EGFR突变NSCLC中检查瘤免疫微环境 (TIME).

主要成果:

EGFR信号产生一个非炎症的时间,阻碍T细胞的透和活动.
EGFR突变NSCLC通常表现为PD-L1表达低和瘤突变负担.
一部分EGFR突变NSCLC患者对ICI有持久的反应.

结论:

尽管面临挑战,但ICI疗法对EGFR突变NSCLC患者的一个子集具有前景.
了解TIME对于改善EGFR突变NSCLC的ICI疗效至关重要.
需要进一步的研究来克服耐药性机制并优化ICI治疗策略.

关键词:

在EGFR的突变中.免疫疗法免疫疗法非小细胞肺癌的肺癌.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...